Clinical trial 1479-0001
An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations.
| Organ | Lung |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Boehringer Ingelheim |
| EudraCT Identifier | 2020-004563-47 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04886804 |
| Last update |